Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University, 20 Renminnan Road, Chengdu 610041, Sichuan, China.
Arch Gynecol Obstet. 2013 Jul;288(1):113-8. doi: 10.1007/s00404-012-2697-4. Epub 2013 Jan 8.
Screening programs based on cytology testing led to the incidence reduction of cervical cancer mortality of about 70-80 % in industrialized countries. However, these favorable results have not been replicated in developing areas. Thus, we aim to evaluate the efficacy of TruScreen (Polartechnics, Sydney, Australia) in detecting of precancerous lesions in comparison with cervical cytology test.
A total of 181 outpatients were screened by TruScreen using the pathological results as the gold standard. The medical records of cytological smear within 6 weeks were obtained from 169 of these participants. The reliability and yield of TruScreen and cytological smear were assessed. The screening results of TruScreen were compared with those obtained from the conventional smear.
The sensitivities for histologically confirmed cervical intraepithelial neoplasia (CIN) lesions by TruScreen and Pap, were 67.4 % (95 % CI 53.4-81.5) and 87.9 % (95 % CI 76.7-99.0), respectively. The specificities for histologically confirmed CIN lesions by TruScreen and Pap, were 68.1 % (95 % CI 60.3-75.9) and 74.3 % (95 % CI 70.0-81.4), respectively. In contrast to Pap smear, TruScreen was comparatively efficacious in screening of cervical cancer (χ (2) = 0.0133, P = 0.9081).
TruScreen is a potential test for initial cervical screening in developing world regions.
细胞学检测为基础的筛查项目使工业化国家的宫颈癌死亡率降低了约 70-80%。然而，这些有利的结果在发展中地区并没有得到复制。因此，我们旨在评估 TruScreen（澳大利亚悉尼 Polartechnics 公司）在检测癌前病变方面的效果，将其与宫颈细胞学检测进行比较。
共有 181 名门诊患者接受了 TruScreen 筛查，以病理结果为金标准。从这 169 名参与者中获得了 6 周内细胞学涂片的病历。评估了 TruScreen 和细胞学涂片的可靠性和检出率。比较了 TruScreen 的筛查结果与传统涂片的结果。
TruScreen 和巴氏涂片对组织学确诊的宫颈上皮内瘤变（CIN）病变的敏感度分别为 67.4%（95%CI 53.4-81.5）和 87.9%（95%CI 76.7-99.0）。TruScreen 和巴氏涂片对组织学确诊的 CIN 病变的特异度分别为 68.1%（95%CI 60.3-75.9）和 74.3%（95%CI 70.0-81.4）。与巴氏涂片相比，TruScreen 在宫颈癌筛查方面更有效（χ(2) = 0.0133，P = 0.9081）。
TruScreen 是发展中地区初始宫颈筛查的一种有潜力的检测方法。
